K Pharma, Net Income Forecast for the Fiscal Year Loss to Narrow

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Jul 14, 2025 3:00 pm JST Revision

4896 K Pharma,Inc. 【J-GAAP】

Guidance Update Report

K Pharma,Inc. <4896> [TSE Growth] announced a performance revision in the afternoon session on July 14th (15:00). The net income/loss (non-consolidated) forecast for the fiscal year ending December 2025 has been revised upward from an expected loss of 1.38 billion yen to a loss of 1.13 billion yen (compared to a loss of 0.84 billion yen in the previous period), indicating a reduction in the loss margin.

At the same time, the January to June period (first half) net income/loss has been revised upward from an expected loss of 0.65 billion yen to a loss of 0.44 billion yen (compared to a loss of 0.42 billion yen in the same period of the previous year), indicating a reduction in the loss margin.

Kabutan News

Guidance Update

First Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2025 Prev	ー	-646	-646	-653	-56.3	0	Feb 13, 2025	J-GAAP
Jan - Jun, 2025 New	ー	-436	-436	-443	-38.2	0	Jul 14, 2025	J-GAAP
Revision Rate	－	+32.5%	+32.5%	+32.2%	+32.2%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2025 Prev	ー	-1,368	-1,368	-1,381	-119.0	0	Feb 13, 2025	J-GAAP
Dec, 2025 New	ー	-1,123	-1,122	-1,136	-97.9	0	Jul 14, 2025	J-GAAP
Revision Rate	－	+17.9%	+18.0%	+17.7%	+17.7%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	0	-423	-422	-426	-36.8	0	Aug 14, 2024	J-GAAP
Jan - Jun, 2025 Guidance	ー	-436	-436	-443	-38.2	0	Jul 14, 2025	J-GAAP
YoY	－	-3.1%	-3.3%	-4.0%	-3.9%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	1,000	366	344	260	25.4	0	Feb 14, 2024	J-GAAP
Dec, 2024	0	-836	-836	-846	-72.9	0	Feb 13, 2025	J-GAAP
Dec, 2025 Guidance	ー	-1,123	-1,122	-1,136	-97.9	0	Jul 14, 2025	J-GAAP
YoY	－	-34.3%	-34.2%	-34.3%	-34.2%